These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 23137576)

  • 41. The year in gout - 2010-2011.
    Crittenden DB; Pillinger MH
    Bull NYU Hosp Jt Dis; 2011; 69(3):257-63. PubMed ID: 22035440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hyperuricemia/gout. Main symptoms of arthropathy. Severe acute joint pain, redness, inflammation].
    Kolyvanos Naumann U; Suter PM; Käser L; Vetter W
    Praxis (Bern 1994); 2005 Apr; 94(14):543-8; quiz 549. PubMed ID: 15849976
    [No Abstract]   [Full Text] [Related]  

  • 43. Recent approaches to gout drug discovery: an update.
    Otani N; Ouchi M; Kudo H; Tsuruoka S; Hisatome I; Anzai N
    Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
    Kamatani N; Hosoya T
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
    [No Abstract]   [Full Text] [Related]  

  • 46. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
    Perez-Ruiz F; Herrero-Beites AM; Carmona L
    Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol].
    Ohno I; Okabe H; Yamaguchi Y; Saikawa H; Uetake D; Hikita M; Gomi H; Ichida K; Hosoya T
    Nihon Jinzo Gakkai Shi; 2008; 50(4):506-12. PubMed ID: 18546882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Febuxostat : a viewpoint by Naomi Schlesinger.
    Schlesinger N
    Drugs; 2008; 68(13):1875-6. PubMed ID: 18729539
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment of asymptomatic hyperuricemia].
    Floege J
    Internist (Berl); 1997 Dec; 38(12):1233. PubMed ID: 9465329
    [No Abstract]   [Full Text] [Related]  

  • 50. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety profile of anti-gout agents: an update.
    Stamp LK
    Curr Opin Rheumatol; 2014 Mar; 26(2):162-8. PubMed ID: 24378930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The efficacy and tolerability of allopurinol dose escalation in patients with gout].
    Radak-Perović M; Zlatković-Svenda M
    Srp Arh Celok Lek; 2013; 141(5-6):333-6. PubMed ID: 23858803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
    Soskind R; Abazia DT; Bridgeman MB
    Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renal function in gout: long-term treatment effects of febuxostat.
    Whelton A; Macdonald PA; Zhao L; Hunt B; Gunawardhana L
    J Clin Rheumatol; 2011 Jan; 17(1):7-13. PubMed ID: 21169856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antihyperuricemic properties of amflutizole in gout.
    Wortmann RL; Ridolfo AS; Lightfoot RW; Fox IH
    J Rheumatol; 1985 Jun; 12(3):540-3. PubMed ID: 3900392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperuricaemia and gout.
    Shipley M
    J R Coll Physicians Edinb; 2011 Sep; 41(3):229-33. PubMed ID: 21949921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Critical revision of the medical treatment of gout in Brazil.
    Azevedo VF; Lopes MP; Catholino NM; Paiva EDS; Araújo VA; Pinheiro GDRC
    Rev Bras Reumatol Engl Ed; 2017; 57(4):346-355. PubMed ID: 28743362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
    Yu KH
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
    Schumacher HR; Chen LX
    Drugs; 2008; 68(13):1875-6. PubMed ID: 18729538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.